You are here

  • Home
  • Archive
  • Volume 13, Issue 5
  • Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab

Citation Tools

Article menu
Download PDFPDF
Colorectal
Original research
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Miller C, Kwok H, Harrow P, et al
Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
Frontline Gastroenterology 2022;13:392-401.